| Primary |
| Product Used For Unknown Indication |
40.0% |
| Depression |
31.1% |
| Drug Use For Unknown Indication |
6.7% |
| Labour Induction |
4.4% |
| Maternal Exposure Timing Unspecified |
4.4% |
| Prophylaxis Of Neural Tube Defect |
4.4% |
| Gestational Diabetes |
2.2% |
| Insomnia |
2.2% |
| Maternal Therapy To Enhance Foetal Lung Maturity |
2.2% |
| Sleep Disorder |
2.2% |
|
| Restlessness |
13.0% |
| Stillbirth |
8.7% |
| Blood Thyroid Stimulating Hormone |
4.3% |
| Completed Suicide |
4.3% |
| Drug Ineffective |
4.3% |
| Drug Interaction |
4.3% |
| Erythema Multiforme |
4.3% |
| Impaired Healing |
4.3% |
| Lip Swelling |
4.3% |
| Oedema Peripheral |
4.3% |
| Overdose |
4.3% |
| Premature Baby |
4.3% |
| Premature Labour |
4.3% |
| Product Quality Issue |
4.3% |
| Prothrombin Level |
4.3% |
| Small For Dates Baby |
4.3% |
| Tardive Dyskinesia |
4.3% |
| Tinnitus |
4.3% |
| Toxicity To Various Agents |
4.3% |
| Urinary Tract Infection |
4.3% |
|
| Secondary |
| Product Used For Unknown Indication |
34.5% |
| Depression |
12.7% |
| Drug Use For Unknown Indication |
10.9% |
| Major Depression |
10.9% |
| Myocardial Ischaemia |
9.1% |
| Accidental Exposure |
5.5% |
| Restless Legs Syndrome |
5.5% |
| Maternal Exposure Timing Unspecified |
3.6% |
| Back Pain |
1.8% |
| Bipolar Disorder |
1.8% |
| Restlessness |
1.8% |
| Sleep Disorder |
1.8% |
|
| Gastric Ulcer Haemorrhage |
13.3% |
| Completed Suicide |
6.7% |
| Multiple Drug Overdose |
6.7% |
| Neonatal Respiratory Distress Syndrome |
6.7% |
| Premature Rupture Of Membranes |
6.7% |
| Prothrombin Level |
6.7% |
| Restlessness |
6.7% |
| Serotonin Syndrome |
6.7% |
| Somnolence |
6.7% |
| Subdural Haemorrhage |
6.7% |
| Syncope |
6.7% |
| Thrombocytopenia |
6.7% |
| Ventricular Tachycardia |
6.7% |
| Weight Increased |
6.7% |
|
| Concomitant |
| Depression |
20.2% |
| Product Used For Unknown Indication |
19.1% |
| Hypertension |
12.2% |
| Prostate Cancer |
8.5% |
| Anxiety |
5.0% |
| Drug Use For Unknown Indication |
3.4% |
| Insomnia |
2.9% |
| Diabetes Mellitus |
2.7% |
| Pulmonary Embolism |
2.7% |
| Rheumatoid Arthritis |
2.7% |
| Atrial Fibrillation |
2.4% |
| Chronic Obstructive Pulmonary Disease |
2.4% |
| Obsessive-compulsive Disorder |
2.4% |
| Cardiovascular Disorder |
2.1% |
| Multiple Sclerosis |
2.1% |
| Bipolar Disorder |
1.9% |
| Essential Hypertension |
1.9% |
| Myocardial Ischaemia |
1.9% |
| Pain |
1.9% |
| Prophylaxis |
1.9% |
|
| Pulmonary Embolism |
11.3% |
| Personality Disorder |
8.5% |
| Weight Decreased |
8.5% |
| Depression |
7.0% |
| Alveolitis Allergic |
5.6% |
| Convulsion |
5.6% |
| Placental Disorder |
5.6% |
| Chronic Obstructive Pulmonary Disease |
4.2% |
| Completed Suicide |
4.2% |
| Fatigue |
4.2% |
| Pancreatic Carcinoma |
4.2% |
| Rash |
4.2% |
| Sleep Disorder |
4.2% |
| Suicide Attempt |
4.2% |
| Weight Increased |
4.2% |
| Cardiac Failure Congestive |
2.8% |
| Renal Failure Acute |
2.8% |
| Urinary Tract Infection |
2.8% |
| Ventricular Fibrillation |
2.8% |
| Visual Impairment |
2.8% |
|
| Interacting |
| Product Used For Unknown Indication |
26.7% |
| Depression |
20.0% |
| Dyslipidaemia |
13.3% |
| Atrial Fibrillation |
6.7% |
| Cardiovascular Event Prophylaxis |
6.7% |
| Deep Vein Thrombosis |
6.7% |
| Depressed Mood |
6.7% |
| Epilepsy |
6.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
6.7% |
|
| Drug Interaction |
50.0% |
| Hypovolaemic Shock |
25.0% |
| International Normalised Ratio Decreased |
25.0% |
|
